LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity

Zaiou, 2003, Antimicrobial and protease inhibitory functions of the human cathelicidin (hCAP18/LL-37) prosequence, J Invest Dermatol, 120, 810, 10.1046/j.1523-1747.2003.12132.x Larrick, 1995, Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein, Infect Immun, 63, 1291, 10.1128/IAI.63.4.1291-1297.1995 Sorensen, 2001, Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3, Blood, 97, 3951, 10.1182/blood.V97.12.3951 Johansson, 1998, Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37, J Biol Chem, 273, 3718, 10.1074/jbc.273.6.3718 Xhindoli, 2014, Native oligomerization determines the mode of action and biological activities of human cathelicidin LL-37, Biochem J, 457, 263, 10.1042/BJ20131048 Tomasinsig, 2009, Structure dependence of biological activities for primate cathelicidins, J Pept Sci, 15, 576, 10.1002/psc.1143 Nijnik, 2009, The roles of cathelicidin LL-37 in immune defences and novel clinical applications, Curr Opin Hematol, 16, 41, 10.1097/MOH.0b013e32831ac517 Kahlenberg, 2013, Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease, J Immunol, 191, 4895, 10.4049/jimmunol.1302005 Xhindoli, 2015, New aspects of the structure and mode of action of the human cathelicidin LL-37 revealed by the intrinsic probe p-cyanophenylalanine, Biochem J, 465, 443, 10.1042/BJ20141016 Yu, 2007, Host defense peptide LL-37, in synergy with inflammatory mediator IL-1beta, augments immune responses by multiple pathways, J Immunol, 179, 7684, 10.4049/jimmunol.179.11.7684 Peric, 2008, IL-17A enhances vitamin D3-induced expression of cathelicidin antimicrobial peptide in human keratinocytes, J Immunol, 181, 8504, 10.4049/jimmunol.181.12.8504 Park, 2011, Regulation of cathelicidin antimicrobial peptide expression by an endoplasmic reticulum (ER) stress signaling, vitamin D receptor independent pathway, J Biol Chem, 286, 34121, 10.1074/jbc.M111.250431 Koeffler, 1985, Gamma-Interferon stimulates production of 1,25-dihydroxyvitamin D3 by normal human macrophages, Biochem Biophys Res Commun, 127, 596, 10.1016/S0006-291X(85)80202-3 Sarker, 2011, Phenylbutyrate counteracts Shigella mediated downregulation of cathelicidin in rabbit lung and intestinal epithelia a potential therapeutic strategy, PLoS ONE, 6, e20637, 10.1371/journal.pone.0020637 Steinmann, 2009, Phenylbutyrate induces antimicrobial peptide expression, Antimicrob Agents Chemother, 53, 5127, 10.1128/AAC.00818-09 Kida, 2006, Sodium butyrate up-regulates cathelicidin gene expression via activator protein-1 and histone acetylation at the promoter region in a human lung epithelial cell line, EBC-1, Mol Immunol, 43, 1972, 10.1016/j.molimm.2005.11.014 Kim, 2009, The effect of calcipotriol on the expression of human beta defensin-2 and LL-37 in cultured human keratinocytes, Clin Dev Immunol, 2009, 645898F, 10.1155/2009/645898 Liu, 2006, Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response, Science, 311, 1770, 10.1126/science.1123933 Gombart, 2009, The vitamin D-antimicrobial peptide pathway and its role in protection against infection, Future Microbiol, 4, 1151, 10.2217/fmb.09.87 Chakraborty, 2008, Bacterial exotoxins downregulate cathelicidin (hCAP-18/LL-37) and human beta-defensin 1 (HBD-1) expression in the intestinal epithelial cells, Cell Microbiol, 10, 2520, 10.1111/j.1462-5822.2008.01227.x Agerberth, 2000, The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations, Blood, 96, 3086, 10.1182/blood.V96.9.3086 Aberg, 2007, Psychological stress downregulates epidermal antimicrobial peptide expression and increases severity of cutaneous infections in mice, J Clin Invest, 117, 3339, 10.1172/JCI31726 Williams, 2009, Transmigration across activated endothelium induces transcriptional changes, inhibits apoptosis, and decreases antimicrobial protein expression in human monocytes, J Leukoc Biol, 86, 1331, 10.1189/jlb.0209062 Mookherjee, 2006, Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37, J Immunol, 176, 2455, 10.4049/jimmunol.176.4.2455 Nagaoka, 2001, Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF-alpha by blocking the binding of LPS to CD14(+) cells, J Immunol, 167, 3329, 10.4049/jimmunol.167.6.3329 Suzuki, 2011, Human anti-microbial cathelicidin peptide LL-37 suppresses the LPS-induced apoptosis of endothelial cells, Int Immunol, 23, 185, 10.1093/intimm/dxq471 Babolewska, 2015, Human-derived cathelicidin LL-37 directly activates mast cells to proinflammatory mediator synthesis and migratory response, Cell Immunol, 293, 67, 10.1016/j.cellimm.2014.12.006 Hu, 2014, Antimicrobial cathelicidin peptide LL-37 inhibits the LPS/ATP-induced pyroptosis of macrophages by dual mechanism, PLOS ONE, 9, e85765, 10.1371/journal.pone.0085765 Tang, 2015, P2X7 receptor regulates internalization of antimicrobial peptide LL-37 by human macrophages that promotes intracellular pathogen clearance, J Immunol, 195, 1191, 10.4049/jimmunol.1402845 Wan, 2014, Cathelicidin LL-37 induces time-resolved release of LTB4 and TXA2 by human macrophages and triggers eicosanoid generation in vivo, FASEB J, 28, 3456, 10.1096/fj.14-251306 Montreekachon, 2011, Involvement of P2X(7) purinergic receptor and MEK1/2 in interleukin-8 up-regulation by LL-37 in human gingival fibroblasts, J Periodontal Res, 46, 327, 10.1111/j.1600-0765.2011.01346.x Neumann, 2014, The antimicrobial peptide LL-37 facilitates the formation of neutrophil extracellular traps, Biochem J, 464, 3, 10.1042/BJ20140778 Neumann, 2014, Novel role of the antimicrobial peptide LL-37 in the protection of neutrophil extracellular traps against degradation by bacterial nucleases, J Innate Immun, 6, 860, 10.1159/000363699 De, 2000, LL-37, the neutrophil granule-and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells, J Exp Med, 192, 1069, 10.1084/jem.192.7.1069 Singh, 2013, The human antimicrobial peptide LL-37, but not the mouse ortholog, mCRAMP, can stimulate signaling by poly(I:C) through a FPRL1-dependent pathway, J Biol Chem, 288, 8258, 10.1074/jbc.M112.440883 Pazgier, 2013, Structural and functional analysis of the pro-domain of human cathelicidin, LL-37, Biochemistry, 52, 1547, 10.1021/bi301008r Wah, 2006, Antimicrobial peptides are present in immune and host defense cells of the human respiratory and gastrointestinal tracts, Cell Tissue Res, 324, 449, 10.1007/s00441-005-0127-7 Jiang, 2012, The effect of human antibacterial peptide LL-37 in the pathogenesis of chronic obstructive pulmonary disease, Respir Med, 106, 1680, 10.1016/j.rmed.2012.08.018 Chen, 2004, Beta-defensins and LL-37 in bronchoalveolar lavage fluid of patients with cystic fibrosis, J Cyst Fibros, 3, 45, 10.1016/j.jcf.2003.12.008 Xiao, 2005, Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation, Chest, 128, 2316, 10.1378/chest.128.4.2316 Golec, 2009, Cathelicidin LL-37, granzymes, TGF-beta1 and cytokines levels in induced sputum from farmers with and without COPD, Ann Agric Environ Med, 16, 289 Sethi, 2008, Infection in the pathogenesis and course of chronic obstructive pulmonary disease, N Engl J Med, 359, 2355, 10.1056/NEJMra0800353 Kilsgard, 2012, Peptidylarginine deiminases present in the airways during tobacco smoking and inflammation can citrullinate the host defense peptide LL-37, resulting in altered activities, Am J Respir Cell Mol Biol, 46, 240, 10.1165/rcmb.2010-0500OC Sun, 2014, LL-37 secreted by epithelium promotes fibroblast collagen production: a potential mechanism of small airway remodeling in chronic obstructive pulmonary disease, Lab Invest, 94, 991, 10.1038/labinvest.2014.86 Zhang, 2014, The human cathelicidin LL-37 enhances airway mucus production in chronic obstructive pulmonary disease, Biochem Biophys Res Commun, 443, 103, 10.1016/j.bbrc.2013.11.074 Yang, 2015, Antimicrobial peptide LL-37 circulating levels in chronic obstructive pulmonary disease patients with high risk of frequent exacerbations, J Thorac Dis, 7, 740 Smith, 1996, Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid, Cell, 85, 229, 10.1016/S0092-8674(00)81099-5 Bals, 2001, Salt-independent abnormality of antimicrobial activity in cystic fibrosis airway surface fluid, Am J Respir Cell Mol Biol, 25, 21, 10.1165/ajrcmb.25.1.4436 Weiner, 2003, The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin, Am J Respir Cell Mol Biol, 28, 738, 10.1165/rcmb.2002-0191OC Sol, 2012, LL-37 induces polymerization and bundling of actin and affects actin structure, PLoS ONE, 7, e50078, 10.1371/journal.pone.0050078 Abou Alaiwa, 2014, pH modulates the activity and synergism of the airway surface liquid antimicrobials beta-defensin-3 and LL-37, Proc Natl Acad Sci U S A, 111, 18703, 10.1073/pnas.1422091112 Benincasa, 2009, Activity of antimicrobial peptides in the presence of polysaccharides produced by pulmonary pathogens, J Pept Sci, 15, 595, 10.1002/psc.1142 Andrault, 2015, Antimicrobial peptide LL-37 is both a substrate of Cathepsins S and K and a selective inhibitor of Cathepsin L, Biochemistry, 54, 2785, 10.1021/acs.biochem.5b00231 Chennupati, 2009, Effects of an LL-37-derived antimicrobial peptide in an animal model of biofilm Pseudomonas sinusitis, Am J Rhinol Allergy, 23, 46, 10.2500/ajra.2009.23.3261 Dean, 2011, Susceptibility of Pseudomonas aeruginosa Biofilm to Alpha-Helical Peptides: d-enantiomer of LL-37, Front Microbiol, 2, 128, 10.3389/fmicb.2011.00128 Nagant, 2012, Identification of peptides derived from the human antimicrobial peptide LL-37 active against biofilms formed by Pseudomonas aeruginosa using a library of truncated fragments, Antimicrob Agents Chemother, 56, 5698, 10.1128/AAC.00918-12 Noore, 2013, Cationic antimicrobial peptide LL-37 is effective against both extra- and intracellular Staphylococcus aureus, Antimicrob Agents Chemother, 57, 1283, 10.1128/AAC.01650-12 Hou, 2013, Antimicrobial peptide LL-37 and IDR-1 ameliorate MRSA pneumonia in vivo, Cell Physiol Biochem, 32, 614, 10.1159/000354465 Liu, 2007, Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin, J Immunol, 179, 2060, 10.4049/jimmunol.179.4.2060 Rahman, 2015, Pulmonary tuberculosis patients with a vitamin D deficiency demonstrate low local expression of the antimicrobial peptide LL-37 but enhanced FoxP3+ regulatory T cells and IgG-secreting cells, Clin Immunol, 156, 85, 10.1016/j.clim.2014.12.003 Hwang, 2014, Serum levels of LL-37 and inflammatory cytokines in plaque and guttate psoriasis, Mediat Inflamm, 2014, 268257, 10.1155/2014/268257 Kubo, 2001, Specific binding and stabilization of DNA and phosphorothioate DNA by amphiphilic alpha-helical peptides, Nucleosides Nucleotides Nucleic Acids, 20, 1313, 10.1081/NCN-100002544 Gilliet, 2008, Antimicrobial peptides and self-DNA in autoimmune skin inflammation, Curr Opin Immunol, 20, 401, 10.1016/j.coi.2008.06.008 Lande, 2007, Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide, Nature, 449, 564, 10.1038/nature06116 Sandgren, 2004, The human antimicrobial peptide LL-37 transfers extracellular DNA plasmid to the nuclear compartment of mammalian cells via lipid rafts and proteoglycan-dependent endocytosis, J Biol Chem, 279, 17951, 10.1074/jbc.M311440200 Peric, 2009, Vitamin D analogs differentially control antimicrobial peptide/alarmin expression in psoriasis, PLoS ONE, 4, e6340, 10.1371/journal.pone.0006340 Harder, 2010, Enhanced expression and secretion of antimicrobial peptides in atopic dermatitis and after superficial skin injury, J Invest Dermatol, 130, 1355, 10.1038/jid.2009.432 Ong, 2002, Endogenous antimicrobial peptides and skin infections in atopic dermatitis, N Engl J Med, 347, 1151, 10.1056/NEJMoa021481 Mallbris, 2010, Injury downregulates the expression of the human cathelicidin protein hCAP18/LL-37 in atopic dermatitis, Exp Dermatol, 19, 442, 10.1111/j.1600-0625.2009.00918.x Tokumaru, 2005, Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37, J Immunol, 175, 4662, 10.4049/jimmunol.175.7.4662 Carretero, 2008, In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37, J Invest Dermatol, 128, 223, 10.1038/sj.jid.5701043 De, 2011, Tight junction defects in patients with atopic dermatitis, J Allergy Clin Immunol, 127, 773, 10.1016/j.jaci.2010.10.018 Akiyama, 2014, The human cathelicidin LL-37 host defense peptide upregulates tight junction-related proteins and increases human epidermal keratinocyte barrier function, J Innate Immun, 6, 739, 10.1159/000362789 Gomes, 2015, Incorporation of antimicrobial peptides on functionalized cotton gauzes for medical applications, Carbohydr Polym, 127, 451, 10.1016/j.carbpol.2015.03.089 Gonzalez-Curiel, 2014, 1,25-dihydroxyvitamin D3 induces LL-37 and HBD-2 production in keratinocytes from diabetic foot ulcers promoting wound healing: an in vitro model, PLOS ONE, 9, e111355, 10.1371/journal.pone.0111355 Gronberg, 2014, Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial, Wound Repair Regen, 22, 613, 10.1111/wrr.12211 Sobczak, 2014, Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases, Pharmacol Rep, 66, 766, 10.1016/j.pharep.2014.04.005 Schauber, 2006, Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases, Eur J Gastroenterol Hepatol, 18, 615, 10.1097/00042737-200606000-00007 Pound, 2015, Cathelicidin antimicrobial peptide: a novel regulator of islet function, islet regeneration and selected gut bacteria, Diabetes, 10.2337/db15-0788 Antoni, 2014, Intestinal barrier in inflammatory bowel disease, World J Gastroenterol, 20, 1165, 10.3748/wjg.v20.i5.1165 Sanchez-Munoz, 2010, TLR9 mRNA expression is upregulated in patients with active ulcerative colitis, Inflamm Bowel Dis, 16, 1267, 10.1002/ibd.21155 Yoo, 2015, Anti-fibrogenic effects of the anti-microbial peptide cathelicidin in murine colitis-associated fibrosis, Cell Mol Gastroenterol Hepatol, 1, 55, 10.1016/j.jcmgh.2014.08.001 Kulkarni, 2015, Phenylbutyrate induces cathelicidin expression via the vitamin D receptor: linkage to inflammatory and growth factor cytokines pathways, Mol Immunol, 63, 530, 10.1016/j.molimm.2014.10.007 Vieira, 2012, Oral administration of sodium butyrate attenuates inflammation and mucosal lesion in experimental acute ulcerative colitis, J Nutr Biochem, 23, 430, 10.1016/j.jnutbio.2011.01.007 Hing, 2013, The antimicrobial peptide cathelicidin modulates Clostridium difficile-associated colitis and toxin A-mediated enteritis in mice, Gut, 62, 1295, 10.1136/gutjnl-2012-302180 Raqib, 2012, Efficacy of sodium butyrate adjunct therapy in shigellosis: a randomized, double-blind, placebo-controlled clinical trial, BMC Infect Dis, 12, 111, 10.1186/1471-2334-12-111 Ren, 2012, Host immune defense peptide LL-37 activates caspase-independent apoptosis and suppresses colon cancer, Cancer Res, 72, 6512, 10.1158/0008-5472.CAN-12-2359 Wu, 2010, The host defense peptide LL-37 activates the tumor-suppressing bone morphogenetic protein signaling via inhibition of proteasome in gastric cancer cells, J Cell Physiol, 223, 178 Limoli, 2014, Cationic antimicrobial peptides promote microbial mutagenesis and pathoadaptation in chronic infections, PLoS Pathog, 10, e1004083, 10.1371/journal.ppat.1004083 Vandamme, 2012, A comprehensive summary of LL-37, the factotum human cathelicidin peptide, Cell Immunol, 280, 22, 10.1016/j.cellimm.2012.11.009